ERα-high ovarian cancer cell lines OVCAR3 and OVCAR8 were treated with a range of doses of ruxolitinib and letrozole at a 1:2 ratio and cell viability was quantified. This evidence concerns the gene ESR1 and ovarian carcinoma.